Clovis takes stock as rival Tesaro shines
Oncology firm could make acquisition if ovarian cancer drug approved.
X
Clovis takes stock as rival Tesaro shines
https://pharmaphorum.com/news/clovis-takes-stock-rival-tesaro-shines/
ESMO2016
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Cancer Market Commentary: Keytruda’s triumph not the last word in NSCLC
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC
Some good news for BMS with Opdivo + natural killer cell combination
But BMS dumps combination with Yervoy.
Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battle
Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Cancer market commentary: 3 highlights from ESMO (Part 1)
Commentary on key cancer data from ESMO by Stephanie Hawthorne
Eye on ESMO: Day 2 – gamechangers take centre stage
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Eye on ESMO: Day 1 – Access in spotlight before data deluge
Europe’s biggest cancer conference ESMO is underway
